5, rue de la Baume
143 articles with Abivax
Abivax Adjusts its 2023 Financial Communication Calendar
Abivax SA announces an update of its 2023 Financial Communications Calendar due to a technical adjustment of the Abivax Board of Director's Meeting to approve the financial statement 2022 as well as the resolutions to be submitted to the General Assembly 2023.
Abivax Does Not Hold Any Cash or Otherwise Have Any Deposits at SVB or at Any Other U.S. Financial Institution
Abivax SA is aware that Silicon Valley Bank was closed on March 10, 2023, by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver.
Abivax Publishes a Prospectus in the Context of its Capital Increase
Abivax announces the availability of a second amendment to its 2022 Universal Registration Document filed with the French Autorité des marchés financiers on April 28, 2022 under number D.22-0372 and of a listing prospectus approved by the AMF under number 23-052 on February 23, 2023, in the context of its reserved capital increase of EUR 130M.
Abivax Appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
Abivax SA announced the appointment of Dr. Sheldon Sloan, M.D., M. Bioethics, as new Chief Medical Officer, effective on March 1, 2023.
Abivax to Present Blood and Rectal Tissue Data from UC Patients Treated with Obefazimod at the 18th Congress of ECCO
Abivax SA (Euronext Paris:FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announced that its scientific abstract has been selected for a poster presentation at the 18th Congress of ECCO taking place on March 1-4, 2023, in Copenhagen, Denmark.
Abivax Publishes Novel Data with Respect to Obefazimod’s Anti-Inflammatory Mechanism of Action
Abivax SA announced the publication of a scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology entitled: "ABX464 up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases." 
Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD
Abivax SA (Euronext Paris:FR0012333284 - ABVX) today announced that the US Food and Drug Administration (the FDA) provided their agreement on the initial Pediatric Study Plan (iPSP) for the development of obefazimod in ulcerative colitis in children from 2 to 17 years old.
Abivax to Attend the J.P. Morgan 41st Annual Healthcare Conference
Abivax SA (Euronext Paris:FR0012333284 - ABVX) today announces that its senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event, both taking place from January 9-12, 2023, in San Francisco, California, US.
First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis
Abivax SA announces that the first patient has been enrolled in the US into its global phase 3 clinical program with product candidate obefazimod for the treatment of moderate to severe ulcerative colitis.
ABIVAX Abstract On Obefazimod Phase 2B Results Selected For Moderated Poster Presentation At UEG Week 2022
Abivax SA announces today that its abstract on the obefazimod interim 48-week safety and efficacy analysis from the ongoing open-label phase 2b maintenance study in moderate to severe ulcerative colitis (UC) has been selected as "one of the best abstracts" for UEG (United European Gastroenterology) Week 2022.
Abivax Presents First-Half 2022 Financial Results and Operations Update
Abivax SA announces its 2022 half-year financial results, as of June 30, 2022, and provides an update on its clinical development progress.
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
Abivax Phase 2b Study Results of Obefazimod (ABX464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology
Abivax SA announces that a scientific article has been published in the peer-reviewed journal "The Lancet Gastroenterology & Hepatology", the world-leading gastroenterology and hepatology research journal.
Abivax Announces a Change in Its Governance
Abivax SA, a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces a transition in the governance of its Board of Directors.
Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval
Abivax SA, a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, received approval from the central US Institutional Review Board for the protocols of the phase 3 induction studies.
Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting
Abivax SA held its ordinary annual and extraordinary general meeting of shareholders on June 9, 2022, which was chaired by Prof. Hartmut Ehrlich, M.D., CEO of Abivax, in the absence of the Chairman of the Board of directors.
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal "Annals of the Rheumatic Diseases" and Selected for Presentation at EULAR 2022
Abivax SA announces that a scientific article on its phase 2a clinical study results for the treatment of moderate to severe active rheumatoid arthritis with obefazimod has been published in the renowned peer-reviewed journal "Annals of the Rheumatic Diseases ".
Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents
Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 9, 2022, at 10:00 a.m., at the offices of Dechert LLP, located at 32 rue de Monceau in Paris, France.